GLP-1 medications represent a class of drugs that were originally developed to treat type 2 diabetes. The name "GLP-1" stands for glucagon-like peptide-1, which is a hormone your body naturally produces. These medications work by mimicking that hormone and triggering responses in your body that help manage blood sugar levels and reduce appetite.
Your Free Guide to Capital One Credit Card Options →
The medications in this class include semaglutide (brand names Ozempic for diabetes, Wegovy for weight management), tirzepatide (Zepbound, Mounjaro), liraglutide (Saxenda, Victoza), and dulaglutide (Trulicity). Each works similarly but has slight differences in how long they stay in your system and how frequently you need to take them. Most are injected weekly, though some are daily oral medications.
What makes these drugs notable in recent years is their secondary effect on weight loss. While they were created to help diabetes patients, many people taking them experienced significant appetite reduction and weight loss as a side benefit. This discovery has expanded their use beyond diabetes treatment, which is why you're seeing them discussed more frequently in mainstream conversations about weight management.
The medications work by slowing how quickly your stomach empties food, increasing feelings of fullness, and signaling your brain that you're satisfied with smaller portions. This mechanism is different from older weight-loss drugs that worked primarily as stimulants. Because of how they function, they're typically prescribed gradually—starting at a low dose and increasing over several weeks.
Takeaway: Understanding that GLP-1s are hormone-mimicking medications originally designed for diabetes helps explain why they work differently from other weight-management drugs and why dosing happens gradually rather than all at once.
GLP-1 medications are among the most expensive prescription drugs on the market today. A month's supply of Wegovy or Zepbound typically costs between $900 and $1,500 without insurance coverage. Mounjaro runs similarly high. These aren't small prices—for context, this often exceeds what people pay monthly for rent or a car payment in many parts of the country.
Get Your Free GameStop Credit Card Information Guide →
The high cost exists for several reasons. First, these drugs are still relatively new to the market, meaning the companies that developed them hold patents. Generic versions don't exist yet, so there's no cheaper alternative manufactured by other companies. Second, the manufacturing process is complex. These medications are biologics, meaning they're made from living cells rather than chemical compounds, which increases production costs significantly. Third, demand has exploded far beyond what manufacturers expected, creating supply constraints that keep prices high.
Insurance coverage varies widely. Some plans cover these medications for diabetes treatment but not for weight management. Others cover both but with high copays—sometimes $200 to $400 per month even after insurance negotiates a lower price. Medicare Part D has covered some GLP-1s for diabetes for years but was slower to cover them for weight management, though this has begun changing. State Medicaid programs have different policies, with some covering them and others not.
For people without insurance, the sticker price is what you'd actually pay if you walked into a pharmacy. Many people are surprised to learn that pharmaceutical companies set these high prices partly because they assume insurance will negotiate them down. Without insurance in the negotiation process, you face the full amount.
Takeaway: GLP-1 costs are high because they're patent-protected biologic drugs with complex manufacturing and enormous demand—understanding this context helps explain why out-of-pocket options require creative strategies rather than quick fixes.
Most GLP-1 manufacturers have recognized that the uninsured population exists and have created programs to reduce out-of-pocket costs. These aren't government programs—they're run by the pharmaceutical companies themselves. If you're uninsured, these represent your most direct path to lower prices, though they still involve meaningful costs.
Learn How USAA Auto Insurance Works →
Novo Nordisk, the company behind Ozempic and Wegovy, offers the Novo Nordisk Patient Assistance Program. Depending on your household income, you might pay $0 to $250 monthly for medications like Wegovy. Eli Lilly, which makes Zepbound and Mounjaro, has the Lilly Insulin Value Program and separate assistance for Zepbound. Novo Nordisk also offers a program called "Wegovy Savings Offer" that caps copays at $99 monthly for uninsured patients, though this may not apply if you're seeking coverage through other routes.
Here's the practical process: You would contact the manufacturer through their website, provide information about your household income and insurance status, and they determine what price tier you fall into based on your financial situation. Income limits are often quite high—some programs assist people earning up to 400% of the federal poverty level, which for a single person in 2024 means up to roughly $55,000 annually. The programs operate on a monthly or quarterly renewal basis, so you need to re-verify your income periodically.
Some programs use vouchers or coupons you present at the pharmacy, while others work through mail-order fulfillment directly from the manufacturer. Processing times vary from a few days to a few weeks. It's worth noting that these programs have been strained by demand—some have temporarily paused enrollment during periods of high volume.
Beyond manufacturer programs, GoodRx and similar discount card services negotiate prices with pharmacies. These aren't insurance but rather membership programs that give you access to negotiated pharmacy pricing. A month of Saxenda, for example, might cost $300 to $500 without a discount card but $200 to $300 with one. The negotiated prices vary by pharmacy location and which discount service you use.
Takeaway: Direct manufacturer assistance and pharmacy discount programs are real tools that can reduce GLP-1 costs for uninsured people, but they require active enrollment steps and come with income thresholds and renewal requirements you'll need to manage.
One path that receives less mainstream attention is participating in clinical research studies. Pharmaceutical companies and research institutions continuously run trials testing GLP-1 medications on different populations, in different doses, and for different conditions. Clinical trial participants receive the study medication at no cost and often receive compensation for their time.
Your Free Guide to AARP Travel Insurance Plans →
Trial participation isn't a quick path—screening and enrollment can take weeks or months. You'll also need to meet specific criteria. Researchers might need people of certain ages, body types, medical histories, or geographic locations. A trial might test Mounjaro in people with type 2 diabetes and obesity, or it might test a new formulation in people with specific underlying health conditions. Not everyone will qualify based on these requirements.
ClinicalTrials.gov is a searchable database maintained by the U.S. National Library of Medicine that lists virtually all clinical trials happening in the United States. You can search by condition, medication, and location. Trial listings include contact information so you can reach out to research coordinators directly. Many academic medical centers and private research organizations conduct these studies and actively recruit participants.
What happens during a trial varies. Some involve frequent clinic visits where you receive injections and have your vital signs checked. Others involve fewer visits with more remote monitoring. Most modern trials compensate participants—amounts range from $50 to several hundred dollars depending on the study's time commitment. All trials require informed consent, meaning researchers must explain the risks and benefits before you participate.
The main drawback is that once the trial ends, the medication stops unless you transition to a manufacturer assistance program or insurance coverage. However, for people who need access now and can commit to the study schedule, this route provides real medication without cost.
Takeaway: Clinical trials offer free GLP-1 medication access in exchange for participation in research, but require meeting specific enrollment criteria and committing to study timelines and monitoring schedules.
Individual states have begun creating their own pathways for GLP-1 access outside traditional insurance. Some state Medicaid programs now cover GLP-1 medications for weight management beyond just diabetes treatment, though coverage varies widely by state. California, Colorado, New York, and several others have expanded coverage. However, Medicaid covers you only if you have low enough income
This guide is for general information only and is not medical, financial, legal, or other professional advice. For decisions specific to your situation, consult a qualified professional. See our Editorial Policy.